<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04993391</url>
  </required_header>
  <id_info>
    <org_study_id>JS111-001-I</org_study_id>
    <nct_id>NCT04993391</nct_id>
  </id_info>
  <brief_title>AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer</brief_title>
  <official_title>A Dose-escalation, Dose-extension and Efficacy-extension, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of AP-L1898 Capsule for the Treatment of the Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Junjing BioSciences Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Junjing BioSciences Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II, open-label, first-in-human clinical study designed to evaluate the&#xD;
      safety, tolerability, PK profile and efficacy of JS111 for patients with Non-small cell lung&#xD;
      cance. This study is divided into 3 periods: dose escalation stage, dose extension stage, and&#xD;
      efficacy extension stage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2021</start_date>
  <completion_date type="Anticipated">August 18, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 18, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by the adverse event</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The AEs summary will be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by the serious adverse event</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The SAEs summary will be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by the physical examinatin</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The abnormal physical examinatin summary will be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by the ECOG score</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The worsening ECOG score summary will be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by the ophthalmic examination</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The ophthalmic examination summary will be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The ORR summary will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>0up to 3 years</time_frame>
    <description>observed maximum plasma concentration of AP-L1898</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to 3 years</time_frame>
    <description>time ro reach maximum plasam concentration of AP-L1898</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-t</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Area under the concentration versus time curve from time 0 to the last measurable concentration (AUC 0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Elimination half life time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>up to 3 years</time_frame>
    <description>apparent clearance (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Apparent volume of distribution (Vd/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR</measure>
    <time_frame>up to 3 years</time_frame>
    <description>the time from the first evaluation of CR or PR to the first evaluation of PD or death for any reason. For the subjects who have no progression but survive persistently after meeting the response criteria, the duration of response will be censored on the date of the last evaluable tumor evaluation or the last follow-up of progression of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Kaplan-Meimer method will be used to plot survival curve, while the median survival will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>up to 3 years</time_frame>
    <description>the proportion of subjects with CR, PR or SD as the best response in accordance with RECIST1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma drug concentration after administration of study drug</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The actual date and time of collection of each PK sample (24h system, accurate to minute) will be recorded in the study. Except an accurate record of the actual time point for collection of PK sample, the administration also needs to be recorded to evaluate PK data. The plasma concentrations of AP-L1898 and its metabolites will be determined using validated LC-MS/MS method.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>40mg dose.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational per</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80mg dose.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational per</description>
  </arm_group>
  <arm_group>
    <arm_group_label>160mg dose.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational pe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>240mg dose.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational pe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>320mg dose.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational pe</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JS111(AP-L1898 Capsules)</intervention_name>
    <description>40 mg, QD</description>
    <arm_group_label>40mg dose.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JS111(AP-L1898 Capsules)</intervention_name>
    <description>80 mg, QD</description>
    <arm_group_label>80mg dose.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JS111(AP-L1898 Capsules)</intervention_name>
    <description>160 mg, QD</description>
    <arm_group_label>160mg dose.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JS111(AP-L1898 Capsules)</intervention_name>
    <description>240 mg, QD</description>
    <arm_group_label>240mg dose.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JS111(AP-L1898 Capsules)</intervention_name>
    <description>320 mg, QD</description>
    <arm_group_label>320mg dose.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        &quot;Inclusion criteria:&#xD;
&#xD;
          1. Age≥18 years, male or female;&#xD;
&#xD;
          2. Patients with histologically or cytologically confirmed locally advanced (stage&#xD;
             IIIB/IIIC) or metastatic (stage IV) NSCLC that can not undergo radical&#xD;
             chemoradiotherapy;&#xD;
&#xD;
          3. Dose-escalation and dose-extension periods: failure of standard of care or intolerance&#xD;
             of standard of care, having received at least one or more systemic therapeutic&#xD;
             regimens for locally advanced or metastatic disease;&#xD;
&#xD;
          4. There is clear evidence showing carrying EGFR exon 20 insertion and other rare EGFR&#xD;
             mutations (only applicable for dose-extension and efficacy-extension periods). The&#xD;
             test method can use: ARMS method for tissue or cell specimen (need to be tested in&#xD;
             national certified laboratory), NGS method for tissue or blood specimen (need to be&#xD;
             tested in CLIA or CAP certified laboratory). Note: enrollment of patients does not&#xD;
             need to be confirmed by central laboratory;&#xD;
&#xD;
          5. At least one measurable lesion meeting RECIST v1.1 definition, no history of puncture&#xD;
             biopsy for the target lesion within the previous two weeks;&#xD;
&#xD;
          6. United States Eastern Cooperative Oncology Group (ECOG) Performance Status score 0~1;&#xD;
&#xD;
          7. Life expectancy &gt;12 weeks;&#xD;
&#xD;
          8. Having adequate function of important organs at screening (requiring no blood&#xD;
             transfusion, no use of hematopoietic stimulating factor or human albumin preparation&#xD;
             within 14 days prior to screening):&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥1.5x109/L;&#xD;
&#xD;
               2. Platelets ≥100×109/L;&#xD;
&#xD;
               3. Haemoglobin &gt; 90 g/L;&#xD;
&#xD;
               4. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5×upper&#xD;
                  limit of normal (ULN) (for known liver metastasis, ≤ 5×ULN);&#xD;
&#xD;
               5. Total bilirubin ≤1.5×ULN;&#xD;
&#xD;
               6. Coagulation function INR≤1.5 ULN;&#xD;
&#xD;
               7. Serum creatinine ≤ 1.5×ULN or creatinine clearance (Ccr, calculated using&#xD;
                  Cockcroft-Gault formula) ≥45 mL/min;&#xD;
&#xD;
               8. Serum lipase and amylase ≤ 1.5 × ULN;&#xD;
&#xD;
          9. Serum pregnancy test must be confirmed as negative for women of childbearing potential&#xD;
             within 7 days prior to enrollment, who agree upon use of effective contraceptive&#xD;
             measures during use of the study drug and within 6 months after the last dose. Women&#xD;
             of childbearing potential in this protocol is defined as sexually mature women: 1) no&#xD;
             hysterectomy or bilateral ovariectomy, 2) uncontinuous natural menopause for 24 months&#xD;
             (i.e., menses occurred at any time in the previous consecutive 24 months; fertility&#xD;
             can not be excluded in case of amenorrhoea following cancer therapy). Male subjects&#xD;
             whose partners are women of childbearing potential must agree to take effective&#xD;
             contraceptive measures during the use of study drug and within 6 months after the last&#xD;
             dose;&#xD;
&#xD;
         10. Being voluntary to participate in this study after sufficient informed consent and&#xD;
             sign the informed consent form.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Use of any chemotherapeutic agen within 14 days prior to the first dose of AP-L1898;&#xD;
             or the time from discontinuation of other investigational product to the use of&#xD;
             anticancer drug less than 5 half-lives or 28 days, whichever is shorter;&#xD;
&#xD;
          2. EGFR exon 20 insertion cohort in efficacy-extension stage: once used the drugs&#xD;
             targeting EGFR exon 20 insertion mutation (e.g., AZD9291, TAK-788, Poziotinib,&#xD;
             CLN-081, JNJ-372, etc.); the patients previously receiving AZD9291 for treatment of&#xD;
             EGFR sensitive mutation are allowed to be enrolled;&#xD;
&#xD;
          3. Ongoing use of CYP3A potent inhibitor or inducer, or discontinuation of potent&#xD;
             inhibitor less than 5 half-lives of the drug, or discontinuation of potent inducer&#xD;
             less than 5 half-lives of the drug or 14 days (whichever is longer) at the first dose&#xD;
             of AP-L1898;&#xD;
&#xD;
          4. Not recovered from the adverse event induced by previous antitumor therapy at&#xD;
             screening (recovered to ≤ grade 1) (except alopecia);&#xD;
&#xD;
          5. Having other malignant tumors within 5 years prior to the start of treatment or&#xD;
             simultaneously (except radically treated non-melanoma without evidence on recurrence&#xD;
             of disease, including skin basal cell carcinoma or squamous cell carcinoma,&#xD;
             breast/cervical carcinoma in situ, superficial bladder cancer and other carcinomas in&#xD;
             situ);&#xD;
&#xD;
          6. Presence of active gastrointestinal disease or other conditions that may obviously&#xD;
             affect absorption, metabolism or excretion of drugs;&#xD;
&#xD;
          7. Patients who known to have received organ transplantation;&#xD;
&#xD;
          8. Major surgery performed within 28 days prior to the first dose. Small surgery&#xD;
             permitted, e.g., minimally invasive biopsy;&#xD;
&#xD;
          9. Patents with carcinomatous meningitis, spinal cord compression at present;&#xD;
&#xD;
         10. At rested state, mean corrected QT interval QTc, using Fridericia's correction&#xD;
             formula&gt;450 ms in man or &gt;470 ms in woman on electrocardiography (ECG) (repeated for&#xD;
             three times). A variety of clinically significant abnormalities in cardiac rhythm,&#xD;
             conduction or morphology of resting ECG, e.g., complete left bundle branch block,&#xD;
             degree III heart block, degree II heart block, PR interval&gt;250 ms. Any factors that&#xD;
             may increase the risk of prolonged QTc interval or risk of arrhythmic events, e.g.,&#xD;
             heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT&#xD;
             syndrome or unexplained sudden death under 40 years of age in lineal relatives, or&#xD;
             ongoing use of any drug known to prolong QT interval;&#xD;
&#xD;
         11. History of poorly controlled hypertension;&#xD;
&#xD;
         12. Previous history of the following diseases: interstitial lung disease, drug-induced&#xD;
             interstitial lung disease, radiation pneumonitis requiring steroid therapy, active&#xD;
             interstitial lung disease with clinical evidence;&#xD;
&#xD;
         13. Patients with active brain metastasis, if the CNS metastasis is only limited to&#xD;
             supratentorial area or cerebellum that has been adequately treated (surgery or&#xD;
             radiotherapy) and radiologically stable for at least 4 weeks, and no corticosteroid is&#xD;
             needed to control symptoms, the patients will be allowed to be enrolled;&#xD;
&#xD;
         14. In acute infection phase and requiring pharmacotherapy;&#xD;
&#xD;
         15. HBV DNA≥103 copies/mL or ≥200 IU/mL when the hepatitis B surface antigen is positive&#xD;
             or hepatitis B core antibody is positive;&#xD;
&#xD;
         16. HCV-RNA &gt; the upper limit of reference at the site when hepatitis C antibody is&#xD;
             positive;&#xD;
&#xD;
         17. Human immunodeficiency virus (HIV) antibody positive;&#xD;
&#xD;
         18. Patient with a previous history of clear mental disorder and taking drugs for&#xD;
             treatment;&#xD;
&#xD;
         19. Patient with a history of drug abuse or drug taking;&#xD;
&#xD;
         20. Pregnant or lactating women;&#xD;
&#xD;
         21. Presence of other factors that may possibly affect the study results, interfere with&#xD;
             their participation in the entire study, including previous or current physical&#xD;
             condition (e.g., ocular disease, including corneal ulcer, conjunctivitis, etc.),&#xD;
             treatment or laboratory examination abnormality, unwillingness to comply with each&#xD;
             procedure, restriction and requirement in the study, as considered by investigators.&#xD;
&#xD;
        A limited list of criteria for selection of participants in the clinical study, provided in&#xD;
        terms of inclusion and exclusion criteria and suitable for assisting potential participants&#xD;
        in identifying clinical studies of interest. Use a bulleted list for each criterion below&#xD;
        the headers &quot;&quot;Inclusion Criteria&quot;&quot; and &quot;&quot;Exclusion Criteria&quot;&quot;. (Limit: 15,000 characters.)&quot;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lina Qin</last_name>
    <phone>86 18600672907</phone>
    <email>lina_qin@junshipharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nong Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yun Fan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caicun Zhou</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 10, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

